Lyra Therapeutics (Nasdaq:LYRA) announced today that it agreed to sell securities in a private placement worth more than $100 million. The company — which develops the XTreo platform designed to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — did not list an intended use […]
Otolaryngology/Ear, Nose & Throat (ENT)
Lucid Diagnostics enrolls first patient in study of esophageal DNA test
Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced today that investigators enrolled the first patient in a study of its EsoGuard. Investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center enrolled the patient in a U.S. Department of Defense-funded study of the EsoGuard esophageal DNA test for at-risk patients with gastroesophageal reflux disease (GERD). Lucid Diagnostics […]
Medtronic launches NuVent eustachian tube dilation balloon
Medtronic (NYSE:MDT) today announced that it launched its NuVent eustachian tube dilation balloon to treat chronic, obstructive eustachian tube dysfunction. The medtech giant designed the NuVent balloon to allow surgeons to deliver treatment in an outpatient setting. It has a flexible balloon section that creates a customized placement option based on unique patient anatomies. Get the […]
FDA approves Cochlear Nucleus Implant for unilateral hearing loss, single-sided deafness
Cochlear Ltd. (ASX:COH) today announced that it received FDA approval for extended applications of its Nucleus implants. Sydney, Australia-based Cochlear designed the Nucleus implants to treat unilateral hearing loss (UHL) and single-sided deafness (SSD). The implants were already FDA approved for those with moderate to profound bilateral sensorineural hearing loss. UHL is characterized by hearing loss […]
Pavmed acquires CapNostics and its esophageal cell collection device
Pavmed (NSDQ:PAVM) announced today that it has agreed to buy CapNostics. The company entered into a definitive membership interest purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina–based CapNostics, according to a news release. CapNostics manufactures the FDA-cleared and CE-marked EsophaCap non-endoscopic esophageal cell collection device used in pre-commercial clinical […]
Pavmed subsidiary Lucid Diagnostics files registration statement for IPO
Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced that Lucid publicly filed a registration statement related to a proposed initial public offering (IPO). The number of shares of common stock and the price range for the offering have not yet been determined, according to a news release. Lucid Diagnostics intends to list its common stock on the Nasdaq market […]
Lyra Therapeutics appoints new CFO
Lyra Therapeutics (NSDQ:LYRA) announced today that it appointed Jason Cavalier as its new chief financial officer, effective today. Cavalier succeeds the company’s current CFO, Don Elsey, who is retiring while he remains expected to serve in an advisory role to assist with the transition. Get the full story at our sister site, Drug Delivery Business News.
Lyra touts non-human trial of XTreo drug-eluting implant
Lyra Therapeutics (NSDQ:LYRA) is touting preclinical data for its XTreo drug-eluting implant for dosing in local sinus tissues. Watertown, Massachusetts-based Lyra’s preclinical results were published — “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses” — were published online in the peer-review journal, American Journal of Rhinology & Allergy. Get the […]
Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment
Impel NeuroPharma (NSDQ:IMPL) announced that it priced an underwritten public offering of common stock worth $45 million. The offering includes 3 million shares of common stock priced to the public at $15 per share, with gross proceeds set to total $45 million before deducting underwriting discounts and commissions and other offering expenses payable by Impel NeuroPharma. […]
AFYX touts trial of biodegradable drug delivery patch
AFYX Therapeutics today touted results from a study exploring the delivery of antibody fragments using the company’s Rivelin technology. The preclinical study, conducted in collaboration with the University of Sheffield in the United Kingdom, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue in mucosal diseases. Get the full story at our sister site, […]
FDA approves Impel NeuroPharma’s nasal spray for treating migraines
Impel NeuroPharma (NSDQ:IMPL) announced today that the FDA approved its Trudhesa nasal spray for treating migraine in adults. Seattle-based Impel NeuroPharma plans to launch Trudhesa commercially early next month. The company’s shares took a massive hit, though, dropping -19.3% at $18.65 per share by market close and continuing to slide down -0.8% at $18.50 after hours […]